Salvage therapy of multiple myeloma: The new generation drugs

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Romano, Alessandra ^a,b,c   Conticello, Concetta ^c   Cavalli, Maide ^c   Vetro, Calogero ^a,c   Di Raimondo, Cosimo ^c   Di Martina, Valentina ^a,c   Schinocca, Elena ^a,c   La Fauci, Alessia ^a,c   Parrinello, Nunziatina Laura ^a,c   Chiarenza, Annalisa ^c   Di Raimondo, Francesco ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Fondazione Veronesi   (Italy)

^c Ospedale Ferrarotto   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENDAMUSTINE; DARATUMUMAB; ELOTUZUMAB; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INDATUXIMAB RAVTANSINE; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; PROTEIN KINASE B INHIBITOR; TABALUMAB; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; HUMAN; MULTIPLE MYELOMA; SALVAGE THERAPY; SIGNAL TRANSDUCTION; CLINICAL TRIAL (TOPIC); METABOLISM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; SALVAGE THERAPY;

EID: 84902204834     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/456037     Document Type: Article

References (59)

1. Kumar S. K., Rajkumar S. V., Dispenzieri A., Lacy M. Q., Hayman S. R., Buadi F. K., Zeldenrust S. R., Dingli D., Russell S. J., Lust J. A., Greipp P. R., Kyle R. A., Gertz M. A., Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 111 5 2516 2520 2-s2.0-41949130070 10.1182/blood-2007-10-116129
2. Lacy M. Q., Hayman S. R., Gertz M. A., Dispenzieri A., Buadi F., Kumar S., Greipp P. R., Lust J. A., Russell S. J., Dingli D., Kyle R. A., Fonseca R., Bergsagel P. L., Roy V., Mikhael J. R., Stewart A. K., Laumann K., Allred J. B., Mandrekar S. J., Rajkumar S. V., Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. Journal of Clinical Oncology 2009 27 30 5008 5014 2-s2.0-73849086725 10.1200/JCO.2009.23.6802
3. Badros A., Burger A. M., Philip S., Niesvizky R., Kolla S. S., Goloubeva O., Harris C., Zwiebel J., Wright J. J., Espinoza-Delgado I., Baer M. R., Holleran J. L., Egorin M. J., Grant S., Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research 2009 15 16 5250 5257 2-s2.0-69349097803 10.1158/1078-0432.CCR-08-2850
4. Rajkumar S. V., Harousseau J., Durie B., Anderson K. C., Dimopoulos M., Kyle R., Blade J., Richardson P., Orlowski R., Siegel D., Jagannath S., Facon T., Avet-Loiseau H., Lonial S., Palumbo A., Zonder J., Ludwig H., Vesole D., Sezer O., Munshi N. C., San Miguel J., Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood 2011 117 18 4691 4695 2-s2.0-79955977910 10.1182/blood-2010-10-299487
5. Kumar S. K., Lee J. H., Lahuerta J. J., Morgan G., Richardson P. G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S. K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J. S., Orlowski R., Palumbo A., Sezer O., Rajkumar S. V., Durie B. G., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012 26 1 149 157 10.1038/leu.2011.196
6. Garderet L., Iacobelli S., Moreau P., Dib M., Lafon I., Niederwieser D., Masszi T., Fontan J., Michallet M., Gratwohl A., Milone G., Doyen C., Pegourie B., Hajek R., Casassus P., Kolb B., Chaleteix C., Hertenstein B., Onida F., Ludwig H., Ketterer N., Koenecke C., van Os M., Mohty M., Cakana A., Gorin N. C., de Witte T., Harousseau J. L., Morris C., Gahrton G., Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation. Journal of Clinical Oncology 2012 30 20 2475 2482 10.1200/JCO.2011.37.4918
7. Berenson J. R., Yellin O., Bessudo A., Boccia R. V., Noga S. J., Gravenor D. S., Patel-Donnelly D., Siegel R. S., Kewalramani T., Gorak E. J., Nassir Y., Swift R. A., Mayo D., Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. The British Journal of Haematology 2013 160 3 321 330 10.1111/bjh.12129
8. Ludwig H., Kasparu H., Leitgeb C., Rauch E., Linkesch W., Zojer N., Greil R., Seebacher A., Pour L., Weissmann A., Adam Z., Bendamustine-bortezomib- dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014 123 7 985 991 10.1182/blood-2013-08- 521468
9. Offidani M., Corvatta L., Maracci L., Liberati A. M., Ballanti S., Attolico I., Caraffa P., Alesiani F., di Toritto T. C., Gentili S., Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal 2013 3, article e162 10.1038/bcj.2013.58
10. Pönisch W., Rozanski M., Goldschmidt H., Hoffmann F. A., Boldt T., Schwarzer A., Ritter U., Rohrberg R., Schwalbe E., Uhlig J., Zehrfeld T., Schirmer V., Haas A., Kreibich U., Niederwieser D., Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. The British Journal of Haematology 2008 143 2 191 200 2-s2.0-52649146310 10.1111/j.1365-2141.2008.07076.x
11. Yong K. L., Williams C. D., Davies F. E., Morgan G. J., Cavenagh J. D., Cook G., Cook M., Coney A.-L., Brown S., Flanagan L. M., Identifying an optimally effective but tolerable dose of bendamustine in combination with thalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2013 122 21, article 286
12. Lentzsch S., 'Sullivan A O., Kennedy R. C., Abbas M., Dai L., Pregja S. L., Burt S., Boyiadzis M., Roodman G. D., Mapara M. Y., Agha M., Waas J., Shuai Y., Normolle D., Zonder J. A., Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012 119 20 4608 4613 10.1182/blood-2011-12-395715
13. Jakubowiak A. J., Siegel D. S., Martin T., Wang M., Vij R., Lonial S., Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F., Reu F. J., Somlo G., Zonder J., Song K., Stewart A. K., Stadtmauer E., Harrison B. L., Wong A. F., Orlowski R. Z., Jagannath S., Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 2013 27 12 2351 2356 10.1038/leu.2013.152
14. Wang M., Martin T., Bensinger W., Alsina M., Siegel D. S., Kavalerchik E., Huang M., Orlowski R. Z., Niesvizky R., Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013 122 18 3122 3128 10.1182/blood-2013-07-511170
15. Stadtmauer E. A., Abonour R., Cohen A. D., Bensinger W., Gasparetto C., Kaufman J. L., Lentzsch S., Vogl D. T., Orlowski R. Z., Kim E. L., Bialas N., Smith D. D., Durie B. G. M., Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood 2013 122 21, article 690
16. Kumar S., Bensinger W., Zimmerman T. M., Reeder C. B., Berenson J. R., Berg D., Hui A.-M., Gupta N., Di Bacco A., Yu J., Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): results from a phase I study after full enrollment. ASCO Meeting Abstracts 2013 31 15, supplement, article 8514
17. Richardson P. G., Siegel D., Baz R., Kelley S. L., Munshi N. C., Laubach J., Sullivan D., Alsina M., Schlossman R., Ghobrial I. M., Doss D., Loughney N., McBride L., Bilotti E., Anand P., Nardelli L., Wear S., Larkins G., Chen M., Zaki M. H., Jacques C., Anderson K. C., Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013 121 11 1961 1967 10.1182/blood-2012-08-450742
18. Miguel J. S., Weisel K., Moreau P., Lacy M., Song K., Delforge M., Karlin L., Goldschmidt H., Banos A., Oriol A., Alegre A., Chen C., Cavo M., Garderet L., Ivanova V., Martinez-Lopez J., Belch A., Palumbo A., Schey S., Sonneveld P., Yu X., Sternas L., Jacques C., Zaki M., Dimopoulos M., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. The Lancet Oncology 2013 14 11 1055 1066 10.1016/S1470-2045(13) 70380-2
19. Larocca A., Montefusco V., Bringhen S., Rossi D., Crippa C., Mina R., Galli M., Marcatti M., La Verde G., Giuliani N., Magarotto V., Guglielmelli T., Rota-Scalabrini D., Omedé P., Santagostino A., Baldi I., Carella A. M., Boccadoro M., Corradini P., Palumbo A., Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013 122 16 2799 2806 10.1182/blood-2013-03-488676
20. Richardson P. G., Wolf J., Jakubowiak A., Zonder J., Lonial S., Irwin D., Densmore J., Krishnan A., Raje N., Bar M., Martin T., Schlossman R., Ghobrial I. M., Munshi N., Laubach J., Allerton J., Hideshima T., Colson K., Poradosu E., Gardner L., Sportelli P., Anderson K. C., Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. Journal of Clinical Oncology 2011 29 32 4243 4249 2-s2.0-81155151824 10.1200/JCO.2010.33. 9788
21. Jakubowiak A. J., Richardson P. G., Zimmerman T., Alsina M., Kaufman J. L., Kandarpa M., Kraftson S., Ross C. W., Harvey C., Hideshima T., Sportelli P., Poradosu E., Gardner L., Giusti K., Anderson K. C., Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a phase I multiple myeloma research consortium study. The British Journal of Haematology 2012 158 4 472 480 10.1111/j.1365-2141.2012.09173.x
22. Dimopoulos M., Siegel D. S., Lonial S., Qi J., Hajek R., Facon T., Rosinol L., Williams C., Blacklock H., Goldschmidt H., Hungria V., Spencer A., Palumbo A., Graef T., Eid J. E., Houp J., Sun L., Vuocolo S., Anderson K. C., Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology 2013 14 11 1129 1140 10.1016/S1470-2045(13)70398-X
23. San-Miguel J. F., Richardson P. G., Gunther A., Sezer O., Siegel D., Blade J., LeBlanc R., Sutherland H., Sopala M., Mishra K. K., Mu S., Bourquelot P. M., Mateos M. V., Anderson K. C., Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. Journal of Clinical Oncology 2013 31 29 3696 3703 10.1200/JCO.2012.46.7068
24. Richardson P. G., Schlossman R. L., Alsina M., Weber D. M., Coutre S. E., Gasparetto C., Mukhopadhyay S., Ondovik M. S., Khan M., Paley C. S., Lonial S., PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013 122 14 2331 2337 10.1182/blood-2013-01-481325
25. Leoni L. M., Bailey B., Reifert J., Bendall H. H., Zeller R. W., Corbeil J., Elliott G., Niemeyer C. C., Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research 2008 14 1 309 317 2-s2.0-40749085662 10.1158/1078-0432.CCR-07-1061 (Pubitemid 351378007)
26. Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H., The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005 90 9 1287 1288 2-s2.0-25444512381 (Pubitemid 41375295)
27. Ponisch W., Bourgeois M., Moll B., Heyn S., Jakel N., Wagner I., Rohrberg R., Hurtz H. J., Schmalfeld M., Assmann M., Edelmann T., Mohren M., Hoffmann F. A., Becker C., Schwarzer A., Schnfelder U., Zehrfeld T., Hensel G., Löschcke K., Krahl R., Ali H. A., Niederwieser D., Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. Journal of Cancer Research and Clinical Oncology 2013 139 3 499 508 10.1007/s00432-012-1339-3
28. Ponisch W., Moll B., Bourgeois M., Andrea M., Schliwa T., Heyn S., Schmalfeld M., Edelmann T., Becker C., Hoffmann F. A., Schwarzer A., Kreibich U., Egert M., Stiegler R., Krahl R., Remane Y., Bachmann A., Lindner T., Weidhase L., Petros S., Fricke S., Vucinic V., Al Ali H., Niederwieser D., Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of Cancer Research and Clinical Oncology 2013 139 11 1937 1946 10.1007/s00432-013-1513-2
29. Ponisch W., Heyn S., Beck J., Wagner I., Mohren M., Hoffmann F. A., Lange T., Schmalfeld M., Zehrfeld T., Schwarzer A., Winkelmann C., Edelmann T., Röhrborn R., Hebenstreit K., Al-Ali H. K., Jäkel N., Niederwieser D., Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO-#077. The British Journal of Haematology 2013 162 2 202 209 10.1111/bjh.12361
30. Romano A., Conticello C., Di Raimondo F., Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 2013 5 4 327 352 10.2217/imt.13.14
31. Lichter D. I., Danaee H., Pickard M. D., Tayber O., Sintchak M., Shi H., Richardson P. G., Cavenagh J., Blade J., Facon T., Niesvizky R., Alsina M., Dalton W., Sonneveld P., Lonial S., van de Velde H., Ricci D., Esseltine D. L., Trepicchio W. L., Mulligan G., Anderson K. C., Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 2012 120 23 4513 4516 10.1182/blood-2012-05-426924
32. Jagannath S., Vij R., Stewart A. K., Trudel S., Jakubowiak A. J., Reiman T., Somlo G., Bahlis N., Lonial S., Kunkel L. A., Wong A., Orlowski R. Z., Siegel D. S., An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia 2012 12 5 310 318 10.1016/j.clml.2012.08.003
33. Siegel D. S., Martin T., Wang M., Vij R., Jakubowiak A. J., Lonial S., Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F., Reu F. J., Somlo G., Zonder J., Song K., Stewart A. K., Stadtmauer E., Kunkel L., Wear S., Wong A. F., Orlowski R. Z., Jagannath S., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012 120 14 2817 2825 10.1182/blood-2012-05-425934
34. Vij R., Wang M., Kaufman J. L., Lonial S., Jakubowiak A. J., Stewart A. K., Kukreti V., Jagannath S., McDonagh K. T., Alsina M., Bahlis N. J., Reu F. J., Gabrail N. Y., Belch A., Matous J. V., Lee P., Rosen P., Sebag M., Vesole D. H., Kunkel L. A., Wear S. M., Wong A. F., Orlowski R. Z., Siegel D. S., An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 119 24 5661 5670 10.1182/blood-2012-03-414359
35. Badros A. Z., Vij R., Martin T., Zonder J. A., Kunkel L., Wang Z., Lee S., Wong A. F., Niesvizky R., Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013 27 8 1707 1714 10.1038/leu.2013.29
36. Siegel D., Martin T., Nooka A., Harvey R. D., Vij R., Niesvizky R., Badros A. Z., Jagannath S., McCulloch L., Rajangam K., Lonial S., Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013 98 11 1753 1761 10.3324/haematol.2013.089334
37. Mikhael J. R., Dingli D., Roy V., Reeder C. B., Buadi F. K., Hayman S. R., Dispenzieri A., Fonseca R., Sher T., Kyle R. A., Lin Y., Russell S. J., Kumar S., Bergsagel P. L., Zeldenrust S. R., Leung N., Drake M. T., Kapoor P., Ansell S. M., Witzig T. E., Lust J. A., Dalton R. J., Gertz M. A., Stewart A. K., Rajkumar S. V., Chanan-Khan A., Lacy M. Q., Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings 2013 88 4 360 376 10.1016/j.mayocp.2013.01.019
38. Papadopoulos K. P., Mendelson D. S., Tolcher A. W., Patnaik A., Burris H. A., Rasco D. W., Bendell J. C., Gordon M. S., Kato G., Wong H., A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX, 0912 in patients with advanced refractory or recurrent solid tumors. ASCO Meeting Abstracts 2011 29 15, supplement, article 3075
39. Stephens T. D., Bunde C. J. W., Fillmore B. J., Mechanism of action in thalidomide teratogenesis. Biochemical Pharmacology 2000 59 12 1489 1499 2-s2.0-0034060666 10.1016/S0006-2952(99)00388-3 (Pubitemid 30229881)
40. Lu G., Middleton R. E., Sun H., Naniong M., Ott C. J., Mitsiades C. S., Wong K. K., Bradner J. E., Kaelin W. G. Jr., The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014 343 6168 305 309 10.1126/science.1244917
41. Gandhi A. K., Kang J., Havens C. G., Conklin T., Ning Y., Wu L., Ito T., Ando H., Waldman M. F., Thakurta A., Klippel A., Handa H., Daniel T. O., Schafer P. H., Chopra R., Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4. The British Journal of Haematology 2014 164 6 811 821 10.1111/bjh.12708
42. Kronke J., Udeshi N. D., Narla A., Grauman P., Hurst S. N., McConkey M., Svinkina T., Heckl D., Comer E., Li X., Ciarlo C., Hartman E., Munshi N., Schenone M., Schreiber S. L., Carr S. A., Ebert B. L., Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014 343 6168 301 305 10.1126/science.1244851
43. Romagné F., André P., Spee P., Zahn S., Anfossi N., Gauthier L., Capanni M., Ruggeri L., Benson D. M. Jr., Blaser B. W., Della Chiesa M., Moretta A., Vivier E., Caligiuri M. A., Velardi A., Wagtmann N., Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009 114 13 2667 2677 2-s2.0-69249108787 10.1182/blood-2009-02- 206532
44. Benson D. M. Jr., Hofmeister C. C., Padmanabhan S., Suvannasankha A., Jagannath S., Abonour R., Bakan C., Andre P., Efebera Y., Tiollier J., Caligiuri M. A., Farag S. S., A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012 120 22 4324 4333 10.1182/blood-2012-06-438028
45. Lacy M. Q., Allred J. B., Gertz M. A., Hayman S. R., Short K. D., Buadi F., Dispenzieri A., Kumar S., Greipp P. R., Lust J. A., Russell S. J., Dingli D., Zeldenrust S., Fonseca R., Bergsagel P. L., Roy V., Stewart A. K., Laumann K., Mandrekar S. J., Reeder C., Rajkumar S. V., Mikhael J. R., Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011 118 11 2970 2975 2-s2.0-80052937408 10.1182/blood-2011-04-348896
46. Gay F., Rajkumar S. V., Coleman M., Kumar S., Mark T., Dispenzieri A., Pearse R., Gertz M. A., Leonard J., Lacy M. Q., Chen-Kiang S., Roy V., Jayabalan D. S., Lust J. A., Witzig T. E., Fonseca R., Kyle R. A., Greipp P. R., Stewart A. K., Niesvizky R., Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. The American Journal of Hematology 2010 85 9 664 669 2-s2.0-77956457402 10.1002/ajh.21777
47. Sinha S., Lacy M., Mikhael J., Hayman S., Buadi F., Detweiler-Short K., Dispenzieri A., Gertz M., Dingli D., Rajkumar S. V., Kumar S. K., Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 2012 26 4 839 841 2-s2.0-84859646589 10.1038/leu.2011.279
48. Harvey R. D., Lonial S., PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncology 2007 3 6 639 647 2-s2.0-38049152900 10.2217/14796694.3.6.639
49. Wolf J. L., Siegel D., Goldschmidt H., Hazell K., Bourquelot P. M., Bengoudifa B. R., Matous J., Vij R., de Magalhaes-Silverman M., Abonour R., Anderson K. C., Lonial S., Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia & Lymphoma 2012 53 9 1820 1823 10.3109/10428194.2012.661175
50. Catley L., Weisberg E., Kiziltepe T., Tai Y., Hideshima T., Neri P., Tassone P., Atadja P., Chauhan D., Munshi N. C., Anderson K. C., Aggresome induction by proteasome inhibitor bortezomib and α -tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006 108 10 3441 3449 2-s2.0-33751172982 10.1182/blood-2006-04-016055
51. Hideshima T., Richardson P. G., Anderson K. C., Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Molecular Cancer Therapeutics 2011 10 11 2034 2042 2-s2.0-81055149914 10.1158/1535-7163.MCT-11-0433
52. Santo L., Hideshima T., Kung A. L., Tseng J. C., Tamang D., Yang M., Jarpe M., van Duzer J. H., Mazitschek R., Ogier W. C., Cirstea D., Rodig S., Eda H., Scullen T., Canavese M., Bradner J., Anderson K. C., Jones S. S., Raje N., Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012 119 11 2579 2589 2-s2.0-84858640254 10.1182/blood-2011-10- 387365
53. Tunquist B. J., Woessner R. D., Walker D. H., Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Molecular Cancer Therapeutics 2010 9 7 2046 2056 2-s2.0-77954615559 10.1158/1535-7163.MCT-10-0033
54. Tai Y., Dillon M., Song W., Leiba M., Li X., Burger P., Lee A. I., Podar K., Hideshima T., Rice A. G., van Abbema A., Jesaitis L., Caras I., Law D., Weller E., Xie W., Richardson P., Munshi N. C., Mathiot C., Avet-Loiseau H., Afar D. E. H., Anderson K. C., Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008 112 4 1329 1337 2-s2.0-51649083849 10.1182/blood-2007-08-107292
55. Zonder J. A., Mohrbacher A. F., Singhal S., van Rhee F., Bensinger W. I., Ding H., Fry J., Afar D. E., Singhal A. K., A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012 120 3 552 559 10.1182/blood-2011-06-360552
56. van Rhee F., Szmania S. M., Dillon M., van Abbema A. M., Li X., Stone M. K., Garg T. K., Shi J., Moreno-Bost A. M., Yun R., Balasa B., Ganguly B., Chao D., Rice A. G., Zhan F., Shaughnessy J. D. Jr., Barlogie B., Yaccoby S., Afar D. E. H., Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics 2009 8 9 2616 2624 2-s2.0-70349481310 10.1158/1535-7163.MCT-09-0483
57. Jakubowiak A. J., Benson D. M., Bensinger W., Siegel D. S., Zimmerman T. M., Mohrbacher A., Richardson P. G., Afar D. E., Singhal A. K., Anderson K. C., Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology 2012 30 16 1960 1965 10.1200/JCO.2011.37.7069
58. Lonial S., Vij R., Harousseau J. L., Facon T., Moreau P., Mazumder A., Kaufman J. L., Leleu X., Tsao L. C., Westland C., Singhal A. K., Jagannath S., Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of Clinical Oncology 2012 30 16 1953 1959 10.1200/JCO.2011.37.2649
59. Lonial S., Jagannath S., Moreau P., Jakubowiak A. J., Raab M. S., Facon T., Vij R., Bleickardt E., Reece D. E., Benboubker L., Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-term safety. ASCO Meeting Abstracts 2013 31 15, supplement, article 8542